Yet how will our system contemplate funding high-cost therapies that deliver potentially curative benefits over such a wide range of years - from 5 to 75 years. …
New CAR-T data once again highlights the evaluation challenge
June 5, 2019 Latest NewsNews of the Day
Latest Video
New Stories
-
Neuren’s first dividend signals a new phase built on DAYBUE royalties
August 26, 2026 - - Australian Biotech -
Starpharma narrows loss as Genentech deal lifts revenue and new funding extends runway
August 26, 2026 - - Australian Biotech -
Genetic Signatures and Microba explore merger to build infectious disease diagnostics group
August 26, 2026 - - Australian Biotech -
Australian company secures European approval for rare disease treatment
August 26, 2026 - - Latest News -
Australia cannot deliver meaningful change until the levers of power are rebalanced
August 26, 2026 - - Latest News -
Professor Brandon Wainwright appointed to lead QIMR Berghofer
August 25, 2026 - - Latest News -
Insurers warn cut could hit Australians most likely to need cancer care
August 25, 2026 - - Latest News